Article Archive
Fall 2025

Fall 2025 Issue

RBD: A Case Study
By James Siberski, MS, CMC, and Carol Siberski, MS, CRmT, C-GCM
Today’s Geriatric Medicine
Vol. 18 No. 4 P. 10

REM Behavior Disorder for the Primary Care Provider and the Patient

Having lectured on rapid eye movement (REM) behavior disorder (RBD) over many years and later developing RBD, I found that lecturing and experiencing are indeed different. Lecturing lacks emotion and is an intellectual exercise, whereas experiencing the disorder revealed frustration and concern about hurting someone or even myself. I decided to discuss RBD so that I could provide primary care physicians (PCPs) and patients the opportunity to understand RBD and expose the nuances of the disorder. This will offer both groups a more global understanding of how treatment and understanding can improve the quality of life for the patient and give the PCP an opportunity to form a helpful therapeutic alliance.

Case Background
The patient is a 6’1” tall 74-year-old male who weighs 185 lbs. His pertinent diagnoses are hypertension, hyperlipidemia, arthritis, and a rash. His medications include nadolol 20 mg tablet, lisinopril 10 mg tablet, 2% steroidal topical cream, fluocinonide 0.05% topical cream, ciclopirox 0.77% topical gel, rosuvastatin 10 mg tablet, various vitamins, and melatonin. The patient describes his health as good. His family history is positive for heart disease, arthritis, Parkinson’s disease (PD), and myasthenia gravis.

The patient began experiencing RBD around November 15, 2023, when, in the middle of the night, he struck his wife in the head, which resulted in no injuries. Other continuing behaviors include kicking legs in the air and shouting very short phrases (eg, “stop,” “help,” and “get out of here”). Prior to retirement, the patient was an assistant professor in gerontology and the director of the master’s level geriatric care management program at a nearby university for more than 20 years. Since he and his spouse are both certified as geriatric care managers, this behavior was immediately recognized as RBD.

The purpose of this case study and discussion is to apprise PCPs of the condition. Although the frequency is low, at 1% to 2% of the US population over the age of 50, it could be 3 to 6 million patients. Keep in mind that numerous patients may not report the behavior or are unaware of the significance of the behavior. If PCPs asked every patient, “When asleep, do you ever yell, kick, punch, or fall out of bed?” and the response was yes, an in-depth evaluation could and should follow. It is both a difficult and time-consuming diagnosis and may require a specialist if one is available. However, the PCP can offer support, provide patient education, and discontinue drugs that may be contributing to RBD.

For example, the nadolol 20 mg tablet could be shifted from the morning to the evening; the steroid cream, which the patient believed exacerbated the RBD, could be limited or completely discontinued, thereby resulting in less frequent and less dramatic occurrences. A sleep diary was kept, noting the presence or absence of RBD, as well as medications and caffeine consumption. It recorded how medications affected sleep, time of day taken, half-life of medications, etc. After several weeks of trial and error, it became clear to the patient what was affecting his RBD.

Additional Insights
In addition, the PCP should also rule out or treat any condition that may contribute to or complicate the behavior. Two articles come to mind for expanding the knowledge of the PCPs. “REM Sleep Behavior Disorder — More Than Just a Parasomnia,” is a superb overview of RBD that defines and discusses the subject from diagnosis to treatment while noting the role of the PCP.1 In addition, “A Neurologist’s Guide to REM Sleep Behavior Disorder” provides more detail and presents a competent discussion on RBD.2 Since there are many additional articles available, it may be prudent for the PCP to research them to expand their fundamental information.

The Four Ds vs Deviant Behavior

Dreams and RBD
Dreams occur as patients sleep during both phases of the sleep cycle (ie, REM and non-REM phases). RBD is a parasomnia defined by intermittent loss of electromyographic atonia during REM sleep with the emergence of complex and vigorous behaviors. Punching, kicking, and leaping from the bed are examples of patients acting out their dreams. Patients can become aggressive during a dream reenactment episode and may present with nonaggressive behavior, such as playing the piano.3

Dementia
RBD is considered prodromal for PD, Lewy body dementia (LBD), multiple system atrophy (MSA), and other conditions. RBD can appear eight years before symptom development, and occurs more frequently in males. Seventy percent to 90% of patients with such diseases eventually develop PD, LBD, or MSA, all of which will present with impaired cognitive functioning.1 At the onset, RBD often starts with small behaviors that can go unnoticed by the bed partner and the patient, indicating that the situation described in this case study may have existed one or two years prior. The patient needs to understand this impact on the average eight-year progression. In addition, the patient needs to be aware that the disease is affecting the brain and that it may be a significant amount of time before symptoms appear.

Drugs
The two drugs noted in most articles for treating RBD are clonazepam and melatonin.1,4 The patient in the case study chose melatonin because the side-effect profile is considered safer when compared with clonazepam, especially in older patients. The patient experimented with extended-release melatonin and quick-dissolve melatonin. The half-life of melatonin is 30 to 50 minutes. A word of caution regarding melatonin: Depending on the dosage and the manufacturer, the melatonin can vary greatly as to the strength and effectiveness of each pill. If not satisfied with the initial results, the individual might switch to another brand before entirely abandoning the melatonin option. The patient in question tried three different suppliers of melatonin before achieving satisfactory results. Ultimately, the patient utilized extended-release and quick-dissolving melatonin twice a night. Since the ideal dosage and timeframe will vary for individuals, the trial-and-error method will be necessary to determine the optimum results. The patient in the case study consumes extended and quick-dissolve tablets daily from 8:00 to 9:00 PM, followed by a lesser dose of quick-dissolve melatonin from 12:30 to 1:00 AM. Applying this approach, his incidences and the severity of REM behavior were significantly reduced.

Numerous other off-label medications are employed to treat RBD but are beyond the scope of the article. Nonetheless, a paper in the Neurotherapeutics journal entitled “Current Concepts and Controversies in the Management of REM Sleep Behavior Disorder” elaborates on the alternatives.

The medications the patient had been using played a role in exacerbating his RBD. The patient was applying prescribed topical creams containing steroids of different strengths (not all at once) for a dermatologic problem. When utilizing these creams, it seemed that the RBD was exacerbated. The stronger the steroid dose, the greater the incidence of REM behavior. Two to three days elapsed before the reaction lessened and then disappeared. His beta-blocker, nadolol, also acted as a trigger for RBD, as did caffeine. Once the patient shifted the beta-blocker to the morning and switched to an over-the-counter antihistamine cream, there was improvement in the RBD. The PCP could review patients’ medications to determine whether any could be contributing to the RBD, or refer them to a clinical pharmacist for review. Many prescription drugs have an impact on sleep, making this determination a difficult task.

Disease vs Deviant Behavior
During his career, the patient lectured on sleep and sleep issues, including RBD. He remembers several individuals who shared a bed with a person with RBD saying that they had left the bed just in time to prevent injury to themselves. RBD ranges from mild to very violent, with both individuals getting hurt. Even pets that sleep on the same bed can be injured or frightened by the behavior. The patient in question calls this run behavior disorder. In this case, the patient has a 9 lb dog that flees when sudden movements or shouting occur.

The individual who has RBD can find it scary, embarrassing, humiliating, frustrating, and, depending on their medical literacy, difficult to understand. As a result, these feelings might prevent the individual with RBD from mentioning it as a problem or issue to the PCP. Hence, it’s advisable to ask the patient whether, during the night, they yell, kick, punch, fall out of bed, or get up and run toward an object in the bedroom. The PCP needs to explain to the patient, as well as others involved in this situation, that their loved ones’ punching or kicking them is not deviant behavior but rather a disease behavior that needs to be addressed.

PCP Recommendations
This author recommends that the PCP utilize the scale noted above, RBD1Q. Ask the patient directly or include it on the annual medical update that patients complete. An affirmative answer by either the patient /or the person sharing the bed with the patient should prompt the PCP to evaluate the patient for RBD. Additionally, the PCP could do the following:

1. Conduct a differential diagnosis to rule out sleep apnea, PTSD, and other causes of the behavior that can be successfully treated.

2. Explain the nature of the disorder in plain terms. Many patients will not understand the loss of atonia, the risk of developing synucleinopathy disease, and other medical terms used when discussing RBD.

3. Discuss treatment options so that the patient can give informed consent. Explain the risks and benefits of clonazepam vs melatonin. Investigate environmental changes that can be made to limit injury to the patient or others (eg, separate beds, padding on the floor to prevent injury to the patient who falls out of bed, etc). Although few specialists are available, refer to any who may be accessible. The PCP could also discuss off-label drugs that are in use if melatonin and clonazepam fail to limit the behaviors.

4. Discuss the concept of disease vs deviant. Since individuals have been hurt by the behavior and have hurt others, it is important to provide that explanation.

5. If the PCP believes the patient needs counseling and/or support concerning RBD being a prodrome for PD, LBD, or MSA, such services could be provided or arranged.

Patient Considerations
1. Describe to the PCP the behavior they are experiencing, and have the bed partner also describe the behavior they have observed or experienced.

2. Ask the PCP for patient educational material and search the internet for reliable sources such as the Mayo Clinic (www.mayoclinic.org/diseases-conditions/rem-sleep-behavior-disorder/diagnosistreatment/drc-20352925) or the American Academy of Sleep Medicine (https://sleepeducation.org/sleep-disorders/rem-sleep-behavior-disorder/)

3. Discuss treatment options and the risks and benefits of the treatments with your PCP.

4. If the patient and PCP decide to utilize melatonin, remember that the United States has no purity laws, so company A’s 5 mg of melatonin may not be the same as company B’s 5 mg. In fact, melatonin is a prescribed medication in many European countries.

5. Review environmental interventions. If the patient falls out of bed, they might consider lowering the bed or using a bedside floor mat, separate beds, etc. An occupational therapy referral might also be helpful.

6. If the patient discovers that caffeine triggers RBD, determine a limited amount of daily caffeine and/or no caffeine after 10 AM. Also, ask the PCP if it is permissible to take medications that trigger the behavior in the morning rather than the evening.

7. Continue all medical treatments prescribed by the PCP.

8. Join a support group if available. Consider support groups for bed partners (See sidebar).

9. Depending on the situation, the patient might want to consult an elder care attorney to arrange for a medical power of attorney, as the duration of the RBD could result in a neurocognitive disorder such as dementia, and the patient may want to plan for this situation.

Conclusion: Friend or Foe
This case study outlines the consequences of RBD and some of the challenges facing the patient, the bed partner, and even the family pet. The case study suggested future consequences facing the individuals involved and the uncertainty of the future. The case also discusses the challenges the PCP faces with a difficult differential diagnosis, providing treatment and explaining the diagnosis and treatment options (as limited as they might be), and then referring to a specialist who may not be available. RBD: Is it a friend or a foe?

Friend: Recognizing and understanding RBD can be positive in that it mitigates the guilt associated with hurting your bed partner. The patient finds comfort and relief in learning that it is disease behavior and not deviant behavior. It allows the patient to plan for the future, such as creating a power of attorney. If there is a need for placement in a facility, the patient could participate in that decision. The patient might volunteer for research into RBD, as clinical trials can lead to prevention, treatment, and improved outcomes for the disease.

Foe: The dreams can be frightening, alarming, and even violent, and cause significant distress for the patient. Many times, RBD causes injury to the patient and others, resulting in guilt and shame. RBD can create a sense of hopelessness, so the patient may withdraw and hide the behavior from the PCP and squander the opportunity for a meaningful intervention.

Substantial work, research, and discovery remain for the medical community when the diagnosis is RBD.

— James Siberski, MS, CMC, retired, was an assistant professor of gerontology and the director of the geriatric care management graduate certificate program at Misericordia University in Dallas, Pennsylvania. He is also an adjunct faculty member at University of Scranton. He has presented more than 150 workshops nationally on various aging-related topics and has been published in numerous professional and trade journals.

— Carol Siberski, MS, CRmT, C-GCM, is a retired geriatric care manager in private practice and has participated in research in geriatrics and intellectual disabilities in Pennsylvania. She has coauthored articles in gerontology and intellectual disabilities.

 

PATIENT RESOURCES
• NAPS Consortium for REM Sleep Behavior Disorder: Has a registry for people with rapid eye movement behavior disorder (RBD), their partners and family, and others who want to learn more.

• American Sleep Association: Offers support groups for people with sleep disorders, including RBD and sleep apnea.

• National Sleep Foundation.

• Hoag Hospital Sleep Disorders Center: Offers support for bed partners.

 

References
1. Coeytaux A, Wong K, Grunstein R, Lewis SJG. REM sleep behaviour disorder — more than just a parasomnia. Aust Fam Physician. 2013;42(11):785-788.

2. Roguski A, Rayment D, Whone AL, Jones MW, Rolinski M. A neurologist's guide to REM sleep behavior disorder. Front Neurol. 2020;11:610.

3. Schenck CH. Update on rapid-eye-movement sleep behavior disorder (RBD): focus on its strong association with α-synucleinopathies. Clin Transl Neurosci. 2023;7(3):19.

4. Gilat M, Coeytaux Jackson A, Marshall NS, et al. Melatonin for rapid eye movement sleep behavior disorder in Parkinson's disease: a randomised controlled trial. Mov Disord. 2020;35(2):344-349.